NCT05292911View on ClinicalTrials.gov

Extension of ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With (NAFLD)

PHASE1CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

March 9, 2022

Primary Completion Date

October 31, 2022

Study Completion Date

October 31, 2022

Conditions
Non-Alcoholic Fatty Liver Disease
Interventions
DRUG

ALT-801

Injected subcutaneously (SC)

OTHER

Placebo

Injected subcutaneously (SC)

Trial Locations (13)

33014

Panax Clinical Research, Miami Lakes

34240

Covenant Research and Clinics, Sarasota

34243

Headlands Research Sarasota, Sarasota

78229

Diagnostics Research Group, San Antonio

Pinnacle Research, San Antonio

78520

South Texas Research Institute, Brownsville

78539

South Texas Research Institute, Edinburg

78745

Accelemed Research Institute, Austin

78757

Pinnacle Research, Austin

84117

Cognitive Clinical Trials, Salt Lake City

89106

Wake Research CRCN, Las Vegas

91763

Catalina Research Institute, Montclair

95648

Clinical Trials Research, Sacramento

Sponsors

Lead Sponsor

Altimmune, Inc.
All Listed Sponsors
lead

Altimmune, Inc.

INDUSTRY

NCT05292911 - Extension of ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With (NAFLD) | Biotech Hunter | Biotech Hunter